these documents elicited concerns from industry and others because they included recommendations to bundle the cost of screening with the cost of confirmatory testing and because they stated that FDA would expect pre market submissions for tests used
in workplace and other sites performing repetitive testing to include the same type of information as submissions for screening tests intended to be used in home settings